Leukemia Posts on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Second-line tyrosine kinase treatment in patients with chronic myeloid leukemia who have failed first-line treatment

Posted by on Apr 3, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate second-line tyrosine kinase inhibitor (TKI) treatment in patients with chronic-phase chronic myeloid leukemia (CP-CML) who had failed first-line TKI treatment.  This study concluded that these patients have good outcomes with second-line TKI treatment.   Some background Tyrosine kinase...

Read More

Evaluating a method to predict the outcomes of patients with chronic myeloid leukemia treated with imatinib

Posted by on Mar 28, 2020 in Leukemia | 0 comments

In a nutshell The study tested whether the EUTOS long-term survival (ELTS) score is efficient to evaluate treatment response in patients with chronic myeloid leukemia (CML), treated with imatinib (Gleevec). The main finding was that ELTS could effectively predict treatment outcomes among such patients in the real world. Some background Initial...

Read More

How did availability of ibrutinib change the treatment of chronic lymphocytic leukemia?

Posted by on Mar 28, 2020 in Leukemia | 0 comments

In a nutshell The study compared treatments in patients with chronic lymphocytic leukemia (CLL), before and after Ibrutinib (Imbruvica) became available in British Columbia, Canada. The authors found that ibrutinib replaced chemoimmunotherapy for treating relapse and improved survival among patients. Some background Chemoimmunotherapy (CIT) was the...

Read More

NCCN guidelines for acute myeloid leukemia

Posted by on Mar 27, 2020 in Leukemia | 0 comments

In a nutshell These guidelines aimed to provide the latest guidelines on managing acute myeloid leukemia.   Some background Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults. Recent advances have led to new treatment options for AML such as targeted therapies and low-intensity...

Read More

Monitoring of asparaginase treatments for childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma

Posted by on Mar 27, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the activity of two types of asparaginase drugs in pediatric patients with acute lymphoblastic leukemia or non-Hodgkin lymphoma. This study concluded that this type of treatment needs close monitoring for optimal effectiveness. Some background Asparaginase (ASNase) is a drug used in the treatment of...

Read More

Risk adjusted treatment of children with non-T cell acute lymphoblastic leukemia

Posted by on Mar 24, 2020 in Leukemia | 0 comments

In a nutshell The study reported the outcomes of children with non-T cell acute lymphoblastic leukemia (ALL) treated with risk-adjusted therapy. The main finding was that patients with standard-risk (SR) ALL had improved survival without cancer-related events. Some background ALL-97 was the first clinical trial performed on Japanese children with ALL....

Read More

Combining obinutuzumab and chlorambucil in unfit patients with chronic lymphocytic leukemia

Posted by on Mar 24, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the effectiveness of combining obinutuzumab (Gazyva) and chlorambucil (Leukeran) (O-Clb) to treat physically unfit patients with chronic lymphocytic leukemia (CLL). The authors found that O-Clb is a safe and effective initial treatment for unfit patients with low-risk CLL in a real-world setting. Some background...

Read More

Evaluating the risk of infection associated with ibrutinib treatment in patients with chronic lymphocytic leukemia

Posted by on Mar 20, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the risk of infection with ibrutinib treatment in B-cell malignancies such as chronic lymphocytic leukemia.  This study concluded that ibrutinib was associated with a higher risk of infections in these patients. Some background B-cell malignancies such as chronic...

Read More